Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN: Cognitive Processing Speed in Relapsing MS with Ozanimod
NCT04140305Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ozanimod in multiple sclerosis (MS), sponsored by Celgene Corporation. Started Jan 2020; status: terminated.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04140305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140305.